Browsing Category
Pharma Industry News
4141 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Takeda (NYSE: TAK) boosts psoriasis ambitions as Phase 3 zasocitinib data sharpen oral TYK2 challenge
Takeda’s Phase 3 zasocitinib psoriasis data could reshape the oral TYK2 race. Read what it means for Takeda, rivals, and the market now.
Kardigan’s tonlamarsen data put acute severe hypertension into sharper commercial focus
Kardigan’s tonlamarsen Phase 2 data showed blood pressure promise despite mixed endpoints. Read what it means for acute severe hypertension next.
Why the IMNN-001 and PARP inhibitor pairing could matter more than the standalone data in ovarian cancer
IMNN-001 plus PARP inhibitors shows extended survival in ovarian cancer. Find out what this means for IMUNON Inc. and future treatment strategies.
Why VG801 could reshape endpoint strategy in inherited retinal disease development
VG801 shows early vision gains in Stargardt disease. Discover how VeonGen Therapeutics is redefining endpoints and regulatory strategy.
FDA engagement signals cautious progress for AEON Biopharma Inc. in complex biologics space (NYSE American: AEON)
AEON Biopharma advances ABP-450 biosimilar strategy. Discover what this means for BOTOX competition, pricing, and biotech market dynamics.
A small imaging trial could reshape how brain metastases are detected and Radiopharm Theranostics is betting on it (ASX: RAD)
Radiopharm Theranostics reports strong RAD 101 interim data in brain metastases imaging. Discover the strategic and market implications.
Can Ocugen, Inc. disrupt chronic eye injections with a single gene therapy procedure? (NASDAQ: OCGN)
Ocugen, Inc. reports Phase 2 gene therapy results that could reshape retinal treatment economics. Discover what this means for investors and competitors.
ImmuPharma (AIM: IMM) advances P140 patent and partnering push with new study data and peer-review manuscript in preparation
ImmuPharma's P140 clears UK patent examination as new study data and Bio-Europe partner meetings strengthen the 2026 licensing case. Read the full analysis.
Is NS002 the catalyst that could finally modernize emergency anaphylaxis treatment? (NYSE: NSRX)
Nasus Pharma Ltd. advances NS002 toward pivotal trials, signaling a potential shift in anaphylaxis treatment. Find out what this means for the market.
Alembic Pharmaceuticals (APLLTD) wins FDA final approval for Paroxetine Extended-Release Tablets
Alembic Pharmaceuticals (APLLTD) wins USFDA final approval for Paroxetine ER 12.5 mg tablets. Read what it means for the US generic pipeline and investor outlook.